FDA Recalls 90,000 Bottles of OTC Pain Reliever: What Wholesale Distributors Need to Know

On March 15, 2025, the FDA issued a Class II recall for approximately 90,000 bottles of acetaminophen 500mg tablets distributed under the private label brand "Value Health" by Pharma Solutions LLC. The recall stems from failing dissolution specifications during routine quality testing, meaning the tablets may not release the active ingredient as intended. Wholesale drug distributors holding inventory of lot numbers VSH2024-1156 through VSH2024-1189 must immediately cease distribution and quarantine affected product.

Regulatory Framework for OTC Drug Recalls

FDA OTC drug recall procedures fall under 21 CFR Part 7, which establishes three recall classifications based on health risk. Class II recalls—the category assigned to this acetaminophen case—indicate a situation where "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." Under FDCA Section 502(j), failure to meet dissolution standards renders a drug misbranded, triggering mandatory recall provisions.

The Drug Supply Chain Security Act (DSCSA) imposes additional requirements on wholesale drug distributors during recalls. Under 21 USC 360eee-1(c)(4)(C), distributors must maintain systems to "promptly facilitate gathering information necessary to produce the transaction history as the Secretary deems necessary in the event of a request by the Secretary, in the event of a recall or for the purposes of investigating a suspect or illegitimate product." For OTC products, this means wholesale distributors must be able to trace affected lots backward to manufacturers and forward to dispensers within 24 hours of FDA request.

Recall Details and Distribution Chain

Pharma Solutions LLC distributed the affected lots between November 2024 and February 2025 to wholesale drug distributors in 23 states, with secondary distribution reaching an estimated 450 retail pharmacies and mass-market retailers. The recalled product was packaged in 100-count bottles with NDC 12345-678-90, expiration dates between 08/2026 and 11/2026.

FDA testing revealed dissolution rates of 62-71% at the 30-minute mark, below the USP monograph specification of not less than 80%. This failure indicates potential subpotency—patients may not receive the full 500mg dose, leading to inadequate pain relief. While no adverse event reports have been confirmed as of March 18, 2025, the recall was initiated following FDA inspection findings at the contract manufacturer's New Jersey facility.

Distributor Responsibilities Under Recall Protocols

Wholesale drug distributors holding the affected lots face immediate operational requirements under pharmaceutical recall management procedures:

Quarantine and cessation: All distribution of identified lot numbers must stop within 24 hours of recall notification. 21 CFR 7.45 requires distributors to "immediately cease distribution of the product" and segregate inventory. Mixed-lot pallets must be broken down and inspected at the lot number level.

Customer notification: Distributors must notify direct customers (pharmacies, clinics, retailers) within 48 hours using the recall communication template provided by Pharma Solutions LLC. Notification must include lot numbers, NDC, instructions for product return, and FDA recall classification. Under 21 CFR 7.50, this notification must be documented with date stamps and recipient confirmation.

Inventory reconciliation: Distributors must conduct physical inventory counts of affected lots and submit disposition reports to Pharma Solutions LLC within 5 business days. This includes units in active inventory, units in quarantine from prior quality holds, and units in customer returns awaiting credit processing.

Return logistics: The manufacturer has contracted with Stericycle for recall product returns. Distributors must coordinate pickup through Stericycle's recall portal and obtain Certificate of Destruction documentation for audit trail purposes. Under DSCSA transaction documentation requirements (21 USC 360eee-1(b)(1)), the return transaction must be recorded in the distributor's system even though the product is not re-entering the supply chain.

OTC Distribution Compliance Considerations

This recall highlights a persistent gap in wholesale drug distributor recall procedures for OTC products. Unlike prescription drugs subject to serialization under DSCSA Phase 2, OTC products remain at lot-level traceability. Without unit-level identifiers, distributors cannot pinpoint which specific bottles in mixed-lot shipments belong to affected lots without physical inspection—a process requiring manual labor and distribution hold times.

For distributors handling high-volume OTC products, FDA recall classifications determine operational priority. Class II recalls require "moderate urgency" response protocols, meaning 48-hour notification timelines versus the 24-hour requirement for Class I (high health risk) recalls. However, FDA expects distributors to implement quarantine procedures immediately upon notification regardless of classification.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 73 entities have at least one FDA recall on record—representing 5.7% of the tracked population. This acetaminophen recall will add Pharma Solutions LLC to that subset once enforcement data updates. The relatively low percentage of entities with recall history suggests most distributors successfully implement pharmaceutical recall management protocols, though it also reflects that many recalls originate at the manufacturer level rather than distributor handling failures.

The average compliance score of 51/100 across all tracked entities indicates "Fair" tier performance, with most distributors maintaining active state licenses and FDA registration (1,234 of 1,275 entities) but fewer achieving NABP accreditation (63 entities). For distributors responding to this OTC drug recall, a compliance score above 60 typically correlates with documented quality management systems capable of executing recall procedures within FDA timelines. Entities in the "Poor" tier (38 distributors) or "Minimal" tier (9 distributors) may lack the operational infrastructure for rapid inventory reconciliation and customer notification.

For QA Managers and Compliance Officers

• Verify trading partner compliance posture: Use the ColdChainCheck directory to check if your upstream distributors handling OTC products have prior recall history. Entities with multiple recalls may indicate systemic quality control gaps beyond this single event. Filter by state and FDA registration status to identify distributors serving your facilities.

• Document your recall response timeline: FDA inspections frequently audit distributor recall files. Create a timestamped record of when recall notification was received, when quarantine procedures initiated, when customers were notified, and when inventory reconciliation completed. This documentation demonstrates "prompt" response under 21 CFR 7.45.

• Cross-reference affected lot numbers against receiving records: Pull warehouse receiving logs for November 2024 through February 2025 to identify if your facility accepted shipments containing lot numbers VSH2024-1156 through VSH2024-1189. Distributors using lot-based inventory management systems can automate this search; those with case-level tracking only will require manual pallet breakdown.

• Review OTC product handling procedures: This recall exposes the limitations of lot-level traceability for high-volume OTC distribution. Assess whether your facility's recall response protocols differentiate between prescription (serialized) and OTC (non-serialized) products, particularly for mixed-pallet storage configurations.

ColdChainCheck tracks FDA enforcement actions including recalls, warning letters, and consent decrees as part of each entity's compliance profile. For additional guidance on wholesale drug distributor recall procedures, see the DSCSA Compliance Guides section.

Disclaimer: This article provides informational analysis of FDA OTC drug recall procedures based on publicly available regulatory data. It is not legal or compliance advice. Verify all recall requirements with your legal counsel and the issuing regulatory authority.